Omer Mohammed

Dr. Omer Mohammed

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
OMOmer Mohammed
Omer Mohammed
SRShabrin Abdul Rasheed
Shabrin Abdul Rasheed
AAAnanya Arora
Ananya Arora
SSSharon Velamparambil Sunny
Sharon Velamparambil Sunny
AKAfthab Salam Kanniyan
Afthab Salam Kanniyan
SKShelby Kutty
Shelby Kutty
Introduction: Mitochondrial dysfunction is recognised as a key driver of heart failure (HF) pathophysiology, contributing to oxidative stress, apoptosis, and impaired energy production in cardiomyocytes. Although therapeutic agents aimed at restoring mitochondrial function have demonstrated promise in animal models and early-phase clinical trials, their efficacy in clinical practice remains uncertain. This meta-analysis evaluated the impact of these agents on clinical outcomes in HF patients. Methods: A systematic literature search was conducted across PubMed, Cochrane Library, ScienceDirect, Google Scholar, and ClinicalTrials.gov for studies published through May 2025. Thirty one studies (24 RCTs and 7 crossover trials) were included in meta-analysis. Standardized mean difference was pooled for changes in left ventricular ejection fraction (LVEF), NYHA class and six-minute walk test (6MWT) distance compared to baseline, and risk ratios (RR) were pooled for heart failure-related hospitalisations, and all-cause mortality. Results: Interventions significantly improved LVEF compared with baseline (SMD: 0.53; 95% CI: 0.42–0.65; p < 0.00001) and control groups (SMD: 0.42; 95% CI: 0.31–0.53). Treatment reduced NYHA functional class (RR: 2.38; 95% CI: 1.48–3.84; p = 0.0004), all-cause mortality (RR: 0.62; 95% CI: 0.47–0.82; p = 0.0007), and HF-related hospitalizations (RR: 0.60; 95% CI: 0.42–0.85; p = 0.004). The certainty of evidence was rated as low across all outcomes owing to substantial heterogeneity and high risk of bias. Discussion: These findings suggest a potential role for mitochondrial-targeted agents as adjunctive strategies in HF, although the evidence base requires further strengthening through high-quality, adequately powered trials before firm clinical recommendations can be made. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251075951 , PROSPERO CRD420251075951.

23 June 2026 in JACC: Advances
Verified
Journal Article
Open access
OMOmer Mohammed
Omer Mohammed
KMKaandeeban Mohanraj
Kaandeeban Mohanraj
DCDiya Chakraborty
Diya Chakraborty
SKSeerat Kular
Seerat Kular
SPSahithi Mani Chandana Paramkusam
Sahithi Mani Chandana Paramkusam
GDGeorge Dangas
George Dangas
Despite successful transcatheter aortic valve implantation (TAVI) for severe aortic stenosis, residual heart failure risk and postprocedural complications persist. The aim was to assess the association between sodium glucose co-transporter 2 inhibitor (SGLT-2i) use and clinical outcomes in patients undergoing TAVI. A systematic search was conducted across PubMed, Cochrane Library, Google Scholar, ScienceDirect, and ClinicalTrials.gov for eligible randomized controlled trials (RCTs) and observational studies. Adjusted HRs and risk ratios were pooled for time-to-event outcomes and dichotomous outcomes, respectively. Risk of bias was assessed using the Risk of Bias 2.0 and Risk of Bias in Non-randomized Studies of Interventions-I tools for RCTs and cohort studies, respectively. Six studies (1 RCT, 5 cohorts) including 35,075 patients were included in the analysis. In pooled analyses, SGLT-2i use was associated with a significantly lower risk of major adverse cardiovascular events (pooled HR: 0.65; 95% CI: 0.44-0.95; P = 0.03; I2 = 26%), heart failure hospitalization (pooled HR: 0.58; 95% CI: 0.40-0.86; I2 = 59%; P = 0.007), all-cause mortality (pooled HR: 0.71; 95% CI: 0.55-0.91; P = 0.007; I2 = 75%), and cardiovascular death (pooled risk ratio: 0.55; 95% CI: 0.34-0.89; P = 0.01; I2 = 36%). The Grading of Recommendations Assessment, Development, and Evaluation assessment was downgraded due to heterogeneity, potential bias, and nonrandomized design of studies. This meta-analysis suggests that peri-operative SGLT-2i use was associated with lower cardiovascular events post-TAVI albeit with low certainty due to predominance of observational studies. These findings are hypothesis generating rather than causal inference. Future clinical trials are warranted.

15 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
Samiullah ShaikhSamiullah Shaikh
Samiullah Shaikh
SSSidra Samad
Sidra Samad
KBKinza Bakht
Kinza Bakht
AMArun Maloth
Arun Maloth
ADAllah Dad
Allah Dad
ABAdnan Bhat
Adnan Bhat
Purpose: Chemotherapy-induced neutropenia (CIN) is a common complication that increases the risk of infection, hospitalization, and treatment delays. While granulocyte colony-stimulating factors (G-CSFs) like filgrastim and pegfilgrastim are used to reduce these risks, limitations in dosing schedules and variability remain. Efbemalenograstim alfa (F-627), a novel long-acting recombinant G-CSF, has emerged as a potential alternative. This systematic review and meta-analysis aimed to evaluate its comparative safety and efficacy against standard G-CSFs in patients undergoing chemotherapy for non-myeloid malignancies. Methods: A comprehensive literature search was conducted across six databases for randomised controlled trials (RCTs) comparing F-627 to standard G-CSFs. Data from three active-controlled trials were pooled using Review Manager (RevMan) 5.4.1, with results expressed as risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes. Heterogeneity was assessed using the I² statistic. Narrative synthesis was performed for the data in the placebo-controlled trial and outcomes with insufficient data for meta-analysis. Risk of bias and evidence quality were evaluated using the Cochrane RoB 2.0 tool and GRADE guidelines, respectively. Results: Four RCTs comprising 973 patients were included, with 533 receiving F-627. F-627 showed comparable efficacy to standard G-CSFs in reducing duration of Grade 4 neutropenia in cycle 1 (MD = 0.04 days; 95% CI: − 0.04 to 0.13; I² = 0%). Incidence of severe neutropenia and febrile neutropenia were also similar (RR = 1.02; 95% CI: 0.97–1.07 and RR = 1.33; 95% CI: 0.41–4.30, respectively). However, a placebo-controlled trial showed a significant reduction in neutropenia and febrile neutropenia incidence with F-627. Secondary outcomes and adverse event profiles were broadly comparable across treatment arms. Conclusion Efbemalenograstim alfa offers a comparable safety and efficacy profile to standard G-CSFs for the prevention of CIN, supporting its role as a viable therapeutic option in non-myeloid cancers.

31 July 2026 in High Blood Pressure & Cardiovascular Prevention
Verified
Journal Article
Open access
PDF file
OMOmer Mohammed
Omer Mohammed
SKSun Hyeok Kim
Sun Hyeok Kim
AKAditya Karthikeyan
Aditya Karthikeyan
NENehal Eid
Nehal Eid
RRRaissa Santos Reimann
Raissa Santos Reimann
MNMichele Nanna
Michele Nanna
Introduction Resistant or poorly controlled hypertension is a major contributor to cardiovascular morbidity and mortality despite contemporary multidrug regimens. Aim This study aimed to evaluate the efficacy and safety of SGLT-2 inhibitors as adjunctive agents to standard antihypertensive therapy in this high-risk population. Methods We systematically searched PubMed, Embase, Google Scholar, the Cochrane Library, ScienceDirect, and ClinicalTrials.gov for randomized controlled trials (RCTs) assessing SGLT-2 inhibitors in adults with poorly controlled hypertension (on ≥2 antihypertensive agents) or resistant hypertension. Primary outcome was the mean change in office systolic blood pressure (SBP). Mean differences (MDs) were pooled for continuous outcomes, and risk ratios (RRs) were pooled for dichotomous outcomes using random-effects models. Results Four RCTs (n=3,718) were included in the meta-analysis. SGLT-2 inhibitors significantly reduced office SBP in both the short term (MD −3.29 mmHg, 95% CI −3.96 to −2.62) and long term (MD −2.96 mmHg, 95% CI −3.58 to −2.35). The overall incidence of adverse events (pooled RR: 0.99, 95% CI 0.95 to 1.02), serious adverse events (pooled RR: 0.92, 95% CI 0.84 to 1.00), AKI (pooled RR: 0.98, 95% CI 0.80 to 1.21), and UTI (pooled RR: 0.88, 95% CI 0.36 to 2.17) were comparable between groups. However, SGLT-2 inhibitors were associated with a significantly increased risk of volume depletion, hypotension, and genital infections. Conclusion SGLT-2 inhibitors provide a modest incremental benefit in lowering office SBP for patients with uncontrolled or resistant hypertension on multidrug regimens with an overall acceptable safety profile. Future dedicated RCTs are warranted. Graphic abstract

20 October 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
MMMegha Mohan
Megha Mohan
OMOmer Mohammed
Omer Mohammed
BABakhtawara Alam
Bakhtawara Alam
SNSidharth Narayanan
Sidharth Narayanan
BBBasil Wahid Bhat
Basil Wahid Bhat
SKShelby Kutty
Shelby Kutty
Background: Obesity is a growing risk factor for cardiovascular disease and mortality in the United States, particularly among younger adults. Methods: Using the Centers for Disease Control and Prevention Wide‐Ranging Online Data for Epidemiologic Research Multiple Cause of Death database, we retrospectively analyzed trends and disparities in obesity‐related cardiac mortality among US individuals aged 15 to 44 years from 1999 to 2023, stratified by sex, race, urbanization, and census region. Deaths were identified using International Classification of Diseases, Tenth Revision ( ICD‐10 ) codes for obesity and cardiac conditions, including ischemic heart disease, sudden cardiac death, arrhythmias, and heart failure. Age‐adjusted mortality rates were calculated using joinpoint regression and expressed as annual percentage change with 95% CIs. Results: Between 1999 and 2023, 51 860 obesity‐related cardiac deaths were recorded. The age‐adjusted mortality rates increased from 0.9 (95% CI, 0.8–0.9) to 2.5 (95% CI, 2.4–2.6) per 100 000. Mortality was highest during the COVID‐19 pandemic (2019–2021). Men consistently had higher age‐adjusted mortality rates than women. Black or African American and American Indian/Alaska Native individuals showed the highest racial disparities. The South and nonmetropolitan areas had the highest regional mortality, with Alaska recording the highest state‐level age‐adjusted mortality rate in 2023 (6.0 per 100 000). Mortality largely returned to baseline across most groups from 2021 to 2023. Conclusions: Obesity‐related cardiac mortality has risen in the United States over the past 2 decades with notable disparities across sex, race, region, and urbanization. These findings underscore the need for targeted public health interventions in high‐risk populations to reduce premature cardiovascular deaths and reverse this trend.